Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients
详细信息 查看全文
- 作者：Laura Boero (1)
Marcos Manavela (1)
Karina Danilowicz (1)
Analia Alfieri (1)
Maria Carolina Ballarino (1)
Alberto Chervin (1)
Natalia García-Basavilbaso (1)
Mariela Glerean (1)
Mirtha Guitelman (1)
Monica Graciela Loto (1)
Jose Alberto Nahmías (1)
Amelia Susana Rogozinski (1)
Marisa Servidio (1)
Nicolas Marcelo Vitale (1)
Débora Katz (1)
Patricia Fainstein Day (1)
Graciela Stalldecker (1)
Maria Susana Mallea-Gil (1) - 关键词：Acromegaly ; IGF ; I ; Growth hormone ; Immunoassay
- 刊名：Pituitary
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：15
- 期：4
- 页码：466-471
- 全文大小：197KB
- 参考文献：1. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558-573 CrossRef
2. Marzullo P, Di Somma C, Pratt KL, Khosravi J, Diamandis A, Lombardi G, Colao A, Rosenfeld RG (2001) Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 86:3001-008 CrossRef
3. Barkan AL (2007) Defining normalcy of the somatotropic axis: an attainable goal? Pituitary 10:135-39 CrossRef
4. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141-148 CrossRef
5. Clemmons DR, Van Wyk JJ (1984) Factors controlling blood concentration of somatomedin C. Clin Endocrinol Metab 13:113-43 CrossRef
6. (2004) Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 89: 3099-102
7. Lim EM, Pullan P (2005) Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. Clin Biochem Rev 26:41-3
8. Clemmons DR (2007) IGF-I assays: current assay methodologies and their limitations. Pituitary 10:121-28 CrossRef
9. Clemmons DR (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57:555-59 CrossRef
10. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-177 CrossRef
11. Massart C, Poirier JY (2006) Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays. Clin Chim Acta 373:176-79 CrossRef
12. Massart C, Poirier JY, Jard C, Pouchard M, Vigier MP (2007) Determination of serum insulin-like growth factor-I reference values for the immunometric Cisbio method on a large number of healthy subjects: clinical utility in the follow-up of patients with treated acromegaly. Clin Chim Acta 381:176-78 CrossRef
13. Clemmons DR, Strasburger C (2004) Monitoring the response to treatment in acromegaly. J Clin Endocrinol Metab 89:5289-291 CrossRef
14. Frystyk J, Freda P, Clemmons DR (2010) The current status of IGF-I assays–a 2009 update. Growth Horm IGF Res 20:8-8 CrossRef
15. Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR (1994) Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 42:145-51 CrossRef
16. Mesiano S, Young IR, Browne CA, Thorburn GD (1988) Failure of acid-ethanol treatment to prevent interference by binding proteins in radioligand assays for the insulin-like growth factors. J Endocrinol 119:453-60 CrossRef
17. Mohan S, Baylink DJ (1995) Development of a simple valid method for the complete removal of insulin-like growth factor (IGF)-binding proteins from IGFs in human serum and other biological fluids: comparison with acid-ethanol treatment and C18 Sep-Pak separation. J Clin Endocrinol Metab 80:637-47 CrossRef
18. Schuller AG, Lindenbergh-Kortleve DJ, de Boer WI, Zwarthoff EC, Drop SL (1993) Localization of the epitope of a monoclonal antibody against human insulin-like growth factor binding protein-1, functionally interfering with insulin-like growth factor binding. Growth Regul 3:32-4
19. Granada ML, Ulied A, Casanueva FF, Pico A, Lucas T, Torres E, Sanmarti A (2008) Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population. Clin Endocrinol (Oxf) 68:942-50 CrossRef
20. Machado EO, Taboada GF, Neto LV, van Haute FR, Correa LL, Balarini GA, Shrank Y, Goulart M, Gadelha MR (2008) Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 18:389-93 CrossRef
21. Cozzi R, Attanasio R, Grottoli S, Pagani G, Loli P, Gasco V, Pedroncelli AM, Montini M, Ghigo E (2004) Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? J Endocrinol Invest 27:1040-047
22. Alexopoulou O, Bex M, Abs R, T’Sjoen G, Velkeniers B, Maiter D (2008) Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93:1324-330 CrossRef
23. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090-098 CrossRef
24. Boguszewski CL (2003) Molecular heterogeneity of human GH: from basic research to clinical implications. J Endocrinol Invest 26:274-88
25. Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC (2002) Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 87:3142-147 CrossRef
26. Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schofl C, Pfeiffer AF (2008) Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 93:1254-262 CrossRef
27. Ho PJ, Jaffe CA, Friberg RD, Chandler WF, Barkan AL (1994) Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors. J Clin Endocrinol Metab 78:1403-410 CrossRef
28. Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) 71:166-70 CrossRef
29. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD (2004) Significance of “abnormal-nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 89:495-00 CrossRef
30. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM (1997) Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82:3187-191 CrossRef
31. Elias PC, Lugao HB, Pereira MC, Machado HR, Castro M, Moreira AC (2010) Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. Horm Metab Res 42:50-5 CrossRef
32. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D’Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G (2003) Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 59:492-99 CrossRef
33. Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94:523-27 CrossRef
34. Karavitaki N, Fernandez A, Fazal-Sanderson V, Wass JA (2009) The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly. Clin Endocrinol (Oxf) 71:840-45 CrossRef
35. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189-202 CrossRef - 作者单位：Laura Boero (1)
Marcos Manavela (1)
Karina Danilowicz (1)
Analia Alfieri (1)
Maria Carolina Ballarino (1)
Alberto Chervin (1)
Natalia García-Basavilbaso (1)
Mariela Glerean (1)
Mirtha Guitelman (1)
Monica Graciela Loto (1)
Jose Alberto Nahmías (1)
Amelia Susana Rogozinski (1)
Marisa Servidio (1)
Nicolas Marcelo Vitale (1)
Débora Katz (1)
Patricia Fainstein Day (1)
Graciela Stalldecker (1)
Maria Susana Mallea-Gil (1)
1. Departamento de Neuroendocrinología (Neuroendocrinology Department), Sociedad Argentina de Endocrinología y Metabolismo, Diaz Velez 3889, (1200), Buenos Aires, Argentina - ISSN：1573-7403
文摘
The aim of our study was to evaluate two different methodologies in IGF-I levels determination, its correlation with GH nadir in OGTT <1 and <0.4?ng/ml and with clinical symptoms in acromegalic patients. We analyzed 37 patients. Sixteen patients had not undergone any kind of treatment (Group 1). Twenty-one patients underwent surgery as primary treatment, and after that, some of them another kind of treatment (except pegvisomant) (Group 2). Serum IGF-I levels were measured by Immulite-1000 (IMM) and by an immunoradiometric assay (DSL) and, GH by immunochemiluminometric assay. IGF-I levels by IMM and by DSL showed a significant difference. When we analyzed in both groups the concordance by crosstabs-Kappa coefficients, between different parameters, GH nadir <1 and <0.4?ng/ml with IGF-I by DSL and IMM showed concordance in group 1, but in group 2 only GH nadir <1 and <0.4?ng/ml had a weak concordance with IGF-I by IMM. When we analyzed clinical symptoms in the patients and, GH nadir <1 and <0.4?ng/ml and IGF-I levels by both methodologies, more than 90% of clinically active patients had abnormal GH response or/and elevated IGF-I levels in group 1, but less than 70% in group 2. In the 8 patients under medical treatment, GH nadir was higher than 0.4?ng/ml in all patients, and IGF-I levels were elevated in 8/8 by DSL and in 6/8 by IMM. In conclusion, discrepant GH and IGF-I levels in the diagnosis and follow-up of patients with acromegaly requires consideration of many factors that influence these parameters.